PET and [F-18]-FDG in oncology: A clinical update

被引:221
作者
Conti, PS
Lilien, DL
Hawley, K
Keppler, J
Grafton, ST
Bading, JR
机构
关键词
positron emission tomography (PET); FDG; oncology;
D O I
10.1016/0969-8051(96)00074-1
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Positron emission tomography (PET) has become a very useful adjunct to anatomic imaging techniques, adding unique information to the characterization of disease. The whole-body PET FDG technique developed over the last few years has surpassed most expectations with respect to its utility in clinical oncology. The large spectrum of neoplasms that now can be studied with this approach makes it an essential clinical imaging tool in diagnosis and management for many patients with cancer. The metabolic information provided by this technique is complementary to results from standard clinical and morphological examinations. It may be anticipated that through application of the multi-modality imaging approach, significant advances in medical care will come.
引用
收藏
页码:717 / 735
页数:19
相关论文
共 228 条
[1]  
Abdel-Nabi H., 1995, Journal of Nuclear Medicine, V36, p106P
[2]   CLINICAL-ASSESSMENT OF THERAPEUTIC EFFECTS ON CANCER USING F-18 2-FLUORO-2-DEOXY-D-GLUCOSE AND POSITRON EMISSION TOMOGRAPHY - PRELIMINARY-STUDY OF LUNG-CANCER [J].
ABE, Y ;
MATSUZAWA, T ;
FUJIWARA, T ;
ITOH, M ;
FUKUDA, H ;
YAMAGUCHI, K ;
KUBOTA, K ;
HATAZAWA, J ;
TADA, M ;
IDO, T ;
WATANUKI, S .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1990, 19 (04) :1005-1010
[3]  
ADLER LP, 1991, J NUCL MED, V32, P1508
[4]   POSITRON EMISSION TOMOGRAPHY OF THYROID MASSES [J].
ADLER, LP ;
BLOOM, AD .
THYROID, 1993, 3 (03) :195-200
[5]   GRADING LIPOSARCOMAS WITH PET USING [F-18] FDG [J].
ADLER, LP ;
BLAIR, HF ;
WILLIAMS, RP ;
PATHRIA, MN ;
MAKLEY, JT ;
JOYCE, MJ ;
ALKAISI, N ;
MIRALDI, F .
JOURNAL OF COMPUTER ASSISTED TOMOGRAPHY, 1990, 14 (06) :960-962
[6]  
Alexander JL, 1976, CLIN NUCL MED, V1, P13, DOI DOI 10.1097/00003072-197606000-00004
[7]  
ALTEHOEFER C, 1995, J NUCL MED, V36, P2056
[8]  
[Anonymous], 1994, CANC FACTS FIG
[9]   A PHASE-II STUDY OF HIGH-DOSE CYCLOPHOSPHAMIDE, THIOTEPA, AND CARBOPLATIN WITH AUTOLOGOUS MARROW SUPPORT IN WOMEN WITH MEASURABLE ADVANCED BREAST-CANCER RESPONDING TO STANDARD-DOSE THERAPY [J].
ANTMAN, K ;
AYASH, L ;
ELIAS, A ;
WHEELER, C ;
HUNT, M ;
EDER, JP ;
TEICHER, BA ;
CRITCHLOW, J ;
BIBBO, J ;
SCHNIPPER, LE ;
FREI, E .
JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (01) :102-110
[10]  
Argenyi E. E., 1995, Journal of Nuclear Medicine, V36, p193P